Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $14.00 USD
Change Today +0.34 / 2.49%
Volume 5.9K
LZAGY On Other Exchanges
SIX Swiss Ex
As of 5:20 PM 10/6/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

Muenchensteinerstrasse 38

Basel, 4002


Phone: 41 61 316 81 11

Fax: 41 61 316 91 11

anhydrides and their derivatives, plasticizers, resins and compounds. Lonza Polymer Intermediates (LPI) is the producer of maleic anhydride catalysts, special anhydrides and esters; and in Europe for maleic anhydride, phthalic anhydride and trimellitic anhydride, fumaric acid and malic acid. Anhydrides and chemicals: The company offers Dibasic acids and anhydrides: phthalic anhydride, maleic anhydride, pyromellitic anhydride, fumaric acid, malic acid, and trimellitic anhydride. It is applicable in unsaturated polyester resins, plasticizers, adhesives, paints, lubricants, additives for food and feedstuffs, pharmaceuticals. The company also offers pure isophthalic acid and meta xylene, which is used for unsaturated polyester resins, PET bottle grade, and paints and coatings. Special anhydrides and esters: The company offers Succinic anhydrides, hydrogenated anhydrides, hardeners for epoxy resins, tetrahydrophthalic, diethylacetonylsuccinate, tetrahydrophthalimide, dimetylsuccinate, and other esters. Its main applications include electrical equipment and electronics, paints and pigments, additives in plastics, pharmaceutical and agricultural products. Plasticizers: The company offers general-purpose and special plasticizers, such as linear phthalates, polymerics, and trimellitates. They are used for PVC, electrical equipment, automotive, furnishing, clothing, and sport area. Resins: The company offers unsaturated polyester resins and derivatives (gel-coats), which is applicable in the nautical engineering, construction and transport industries, electrotechnical equipment, sport, furniture, and sanitary wear areas. Compounds: The company offers Technocompounds and molded composites, such as BMC, SMC, and TMC. They are applicable in the electrical equipment and electronics, construction and transport industries. Catalysts and technologies: The company offers catalysts and technologies, and custom manufacturing of catalysts. They are used in the production of phthalic and maleic anhydride, pyromellitic anhydride and formaldehyde. Markets The company operates primarily in Switzerland, European Union, Rest of Europe and North America. Significant Events On May 18, 2009, The European Commission has approved the proposed joint venture of Teva Pharmaceutical Industries Ltd. and Lonza Group AG. Teva and Lonza have signed an agreement to establish a joint venture to develop, manufacture, and market a portfolio of biosimilars. Through this joint venture, Teva and Lonza would co-operate to develop, manufacture, and market efficacious, and safe generic equivalents of a selected portfolio of biologic pharmaceuticals. Lonza Group AG and Singapore's Bio*One Capital have entered into a joint venture, Lonza Biologics Tuas, to build a large-scale mammalian cell-culture facility in Singapore for the manufacture of commercial biopharmaceuticals. Lonza Group AG has formed a strategic manufacturing alliance with Solvay Pharmaceuticals. Under the terms of the long-term strategic cooperation, Lonza would produce a selection of Solvay's large volume active pharmaceutical ingredients (APIs). In December 2007, Lonza Group AG has entered into a strategic alliance with BioWa, Inc. to generate an optimized production platform for potent antibodies. Teva Pharmaceutical Industries Ltd. and Lonza Group AG formed a joint venture to develop, manufacture and market biosimilars. Both companies intends to explore additional biosimilars opportunities outside the partnership. On June 8, 2009, The European Commission has cleared the proposed biosimilars joint venture between Teva Pharmaceutical Industries Limited and Lonza Group AG.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LZAGY:US $14.00 USD +0.34

LZAGY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ashland Inc $103.61 USD -1.17
Clariant AG SFr.17.26 CHF +0.31
Croda International PLC 2,777 GBp +11.00
Owens Corning $42.49 USD -2.19
PerkinElmer Inc $46.74 USD -0.06
View Industry Companies

Industry Analysis


Industry Average

Valuation LZAGY Industry Range
Price/Earnings 32.1x
Price/Sales 1.8x
Price/Book 3.4x
Price/Cash Flow 32.4x
TEV/Sales 1.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LONZA GROUP AG-UNSPON ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at